Pfizer announced the M&A event of the year with its Biohaven acquisition. Top investors turned to Tegus for on-demand insight on Nurtec’s trajectory, Biohaven’s leadership, and the competitive environment. See for yourself with a free Tegus trial.
It’s survival of the fittest, and BridgeBio Pharma is cutting fat—shedding any and all extra costs in an attempts to stay afloat in a prolonged bear market. CEO Neil Kumar, Ph.D., hopes the industry will take notes to ultimately embolden a better biotech frontier.
Approved three years ago as a solo agent for certain patients with IDH1-mutated acute myeloid leukemia, Servier’s Tibsovo has now scored a wider indication as the company works to expand its use. The blessing is further evidence that Servier made a smart buy last April when it acquired Agios Pharma’s oncology assets—led by Tibsovo—for $1.8 billion.
Pharmacy groups are pressing the FTC to scrutinize several contracting practices initiated by PBMs, including claw back fees and steering patients towards PBM-affiliated facilities.
If there’s one positive outcome of the COVID-19 pandemic, it’s the speed at which diagnostic test makers learned to develop and begin churning out kits to test for a virus.
Janssen India is looking to the younger generation to help fight the country's TB epidemic with assistance from a famous Bollywood actress and an Indian hip-hop star.
The joint venture will develop a range of new kidney care tech, with a specific focus on at-home treatments that’ll make dialysis more easily accessible, offering an alternative to the typical schedule of in-clinic sessions three times a week.
There goes another one. After a who’s who of biopharmas failed the NIH’s inpatient COVID-19 study, NRx Pharmaceuticals has now flunked a related trial in severely ill patients, sending its share price down to the basement.
"Every healthcare organization and every healthcare leader should be standing tall right now to advocate for action from Congress," said Northwell Health CEO Michael Dowling.
Those in the U.K. with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) finally have fully-funded treatment option. England’s National Institute for Health and Care Excellence (NICE) has signed off on Sanofi and Regeneron’s Libtayo for the tough-to-treat skin cancer, allowing patients in the U.K. fully funded access to the drug.
U.S. officials have arrested Enochian BioSciences co-founder Serhat Gümrükcü. The researcher is charged with conspiring to use interstate commerce facilities in the commission of murder-for-hire which resulted in a death.
